Detail akcie Evotec OAI online

Business Summary: Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Evotec SE revenues increased 4% to EUR781.4M. Net loss decreased 52% to EUR83.9M. Revenues reflect EVT Innovate segment increase of 30% to EUR266.9M, United States segment increase of 10% to EUR459.4M. Lower net loss reflects EVT Innovate segment loss decrease of 62% to EUR4.5M. Basic Earnings per Share excluding Extraordinary Items increased from -EUR0.99 to -EUR0.47.